Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: Breast Cancer
Interventions: OTHER: None (Observational study)
Sponsor: AstraZeneca
Collaborators: Daiichi Sankyo